Explore Our Network

4M Therapeutics is a biotechnology company specializing in the discovery and development of targeted therapies for neuropsychiatric and neurodegenerative diseases such as bipolar disorder and Alzheimer's disease. Leveraging a human brain cell platform derived from induced pluripotent stem cells, the company advances small molecule and peptide drug candidates that modulate pathways involved in neuronal health. 4M Therapeutics integrates biomarker-driven drug development and strong academic collaborations to enable predictive and safe preclinical drug discovery, aiming to advance targeted CNS therapies with improved safety and efficacy profiles.

Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.

Adaptyx Biosciences is developing a wearable platform for continuous monitoring of multiple biomarkers in dermal interstitial fluid from a single device at the point of need. Built on programmable molecular switch technology that can be reprogrammed across hormones, drugs, electrolytes, peptides, and proteins, it is a single platform adaptable to needs spanning Military Operational Medicine, Combat Casualty Care, Military Infectious Diseases, Clinical and Rehabilitative Medicine, and Chemical, Biological, and Radiological Defense. The platform draws on more than 17 years of pioneering research from our team at Stanford. We have prototype sensors ready for R&D today, and have already demonstrated continuous measurement of multiple biomarkers in humans, including multi-day free cortisol monitoring that captures the diurnal rhythm conventional single-timepoint tests cannot see.

Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Caleo Biotechnologies develops advanced human tissue models to enable more predictive and clinically relevant preclinical research, with a focus on fibrotic and inflammatory diseases. Their core platform integrates epithelial, immune, and mesenchymal/stromal compartments into self-organizing, patient-derived 3D tissue models. These models are used to study disease mechanisms, evaluate drug responses, and de-risk therapy development by capturing patient-specific biology and microenvironmental interactions. Caleo also combines these systems with molecular analysis and scalable, AI-driven analytics to support drug discovery and translational research.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.

Chariot Biosciences develops next-generation cell and gene therapies for chronic diseases, focusing on innovative, long-lasting solutions that minimize the need for frequent injections. The company's proprietary platform is based on engineered symbiotic microbes designed to provide sustained delivery of therapeutic proteins and peptides after a single injection. Chariot targets chronic conditions such as Gaucher disease, diabetes, and cancer, aiming to improve patient adherence, reduce logistical challenges, and replace standard frequent biologic dosing.

ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.

CMC Pharmaceuticals, Inc. provides integrated services supporting drug development for small molecule therapeutics and medical countermeasures. The company offers comprehensive solutions for formulation and process development, analytical method validation, stability and compatibility testing, manufacturing oversight, and regulatory support across all phases—including specialized expertise in handling highly potent compounds and government MCM (Medical Countermeasure) programs. In-house laboratories and robust regulatory systems ensure submission-ready, compliant data, addressing the safety and operational requirements of both commercial and defense sectors.

CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.

Cocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.

Cytonus Therapeutics is pioneering the convergence of artificial intelligence and synthetic biology to revolutionize drug development and delivery. The company challenges the high failure rates of traditional and precision medicines by developing next-generation therapeutics that are both highly effective and safe. Their mission is to create pragmatic shifts in how drugs are designed and administered, focusing on precision, safety, and efficacy to improve patient outcomes.